ArticleEuropean journal of medical research2025
Superselective transarterial chemoembolization (SSTACE) as second-line conversion therapy for locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma: a preliminary retrospective cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIn patients with locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma, conversion therapy has shown suboptimal efficacy, typically resulting in stable disease (SD) or progressive disease (PD) leading to low surgical conversion rates and unfavorable prognosis. This study seeks to assess the efficacy and safety of superselective transarterial chemoembolization (SSTACE) in treating this specific patient cohort.
methodsThis retrospective cohort study analyzed patients diagnosed with locally advanced unresectable gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma at the Affiliated Hospital of North Sichuan Medical College between January 2019 and March 2025. All of them underwent a single session of SSTACE, followed by an assessment of surgical resectability one month later. Patients considered resectable underwent gastrectomy with D2 lymphadenectomy, while those deemed unresectable continued with palliative chemotherapy regimens consistent with their pre-SSTACE systemic protocols. The primary endpoint was R0 resection rate, with secondary endpoints, including the postoperative complication rate, tumor regression rate post-chemoembolization, and pathological complete response (pCR) rate.
resultsThis retrospective study analyzed 16 patients who underwent SSTACE. Tumor regression was observed in 12 patients, eight of whom met the criteria for partial response. In addition, 12 patients who exhibited regression subsequently achieved R0 resection. Pathological complete response (pCR) was observed in three patients. In terms of safety, all adverse events related to SSTACE in the cohort were manageable. The most common adverse events were nausea (43.8%, 7/16), vomiting (37.5%, 6/16), and abdominal pain (37.5%, 6/16). No instances of hepatic dysfunction were reported. In addition, none of the surgical patients experienced major postoperative complications.
conclusionsSSTACE could potentially offer a novel therapeutic approach for patients with locally advanced unresectable GC or GEJ cancer who have shown limited response to systemic chemotherapy/immunotherapy, characterized by SD or PD. This treatment may increase the likelihood of achieving surgical conversion and R0 resection rates while upholding a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.